Black Diamond Therapeutics, Inc. (BDTX)

Silevertinib, Black Diamond Therapeutics' lead asset, showed strong Phase 2 results with 60% ORR and 86% CNS ORR. Read why BDTX stock is a Buy.

Becton Dickinson (BDX) Analyst Rating Update - %B %d, %Y On %B %d, %Y, Evercore ISI Group maintained an 'Outperform' rating for Becton Dickinson (BDX) while

The stock’s fifty day simple moving average is $2.33 and its 200 day simple moving average is $2.41. The firm has a market capitalization of $115.17 million, a P/E ratio of -2.61 and a beta of 3.25. Black Diamond Therapeutics (NASDAQ:BDTX – Get Free Report) last posted its earnings results ...

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) - HC Wainwright upped their Q1 2026 earnings estimates for shares of Black Diamond Therapeutics in a research note issued on Wednesday, April 29th. HC Wainwright analyst R. Burns now anticipates that the company will earn ($0.18) per share

Black Diamond Therapeutics reported a $9.0M Q1 2026 net loss after last year’s $70.0M Servier upfront, while R&D fell to $7.0M and cash plus investments reached $118.3M, funding operations into the second half of 2028.